Drugs / GDC-0927
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02316509 | Mar 2015 → Jan 2020 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-0927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02316509 ↗ |
| Known as | RG-6047 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297758 ↗ |
| Route | Oral | “GDC-0927 will be administered orally as a single dose on Day -7.” NCT02316509 ↗ |